Literature DB >> 32856128

Calcinosis in Systemic Sclerosis: Updates in Pathophysiology, Evaluation, and Treatment.

Carrie Richardson1,2, Anna Plaas3, John Varga4.   

Abstract

PURPOSE OF REVIEW: Calcinosis is a common complication of systemic sclerosis with no known effective pharmacologic therapy. We reviewed the literature regarding systemic sclerosis-related calcinosis as well as other disorders of biomineralization in order to identify targets of future study for calcinosis. RECENT
FINDINGS: Patients with systemic sclerosis-related calcinosis demonstrate systemic abnormalities in mineralization pathways, including decreased levels of the mineralization inhibitor inorganic pyrophosphate. Insights from other mineralization disorders suggest that local and systemic phosphate metabolism pathways involving the ABCC6, ENPP1, and NT5E genes play a critical role in regulation of ectopic calcification. Knockout models of these genes may lead to an appropriate murine model for study of calcinosis. Poly(ADP-ribose) polymerase (PARP) enzymes may also play a critical role in hydroxyapatite nucleation and warrant future study in systemic sclerosis. Study of local and systemic mineralization pathways, particularly phosphate metabolism pathways and PARP enzymes, should provide greater insight into the pathogenesis of systemic sclerosis-related calcinosis.

Entities:  

Keywords:  Calcinosis; Systemic sclerosis

Year:  2020        PMID: 32856128     DOI: 10.1007/s11926-020-00951-2

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  4 in total

Review 1.  Subcutaneous calcinosis: Is it different between systemic sclerosis and dermatomyositis?

Authors:  Antonia Valenzuela; Lorinda Chung
Journal:  J Scleroderma Relat Disord       Date:  2021-10-28

Review 2.  Calcinosis in systemic sclerosis.

Authors:  Srijana Davuluri; Christian Lood; Lorinda Chung
Journal:  Curr Opin Rheumatol       Date:  2022-08-19       Impact factor: 4.941

3.  Relationship between ectopic calcifications and bone fragility depicted on computed tomography scan in 70 patients with systemic sclerosis.

Authors:  Marine Fauny; Elodie Bauer; Edem Allado; Eliane Albuisson; Joëlle Deibener; François Chabot; Damien Mandry; Olivier Huttin; Isabelle Chary-Valckenaere; Damien Loeuille
Journal:  J Scleroderma Relat Disord       Date:  2022-06-28

4.  Inorganic pyrophosphate is reduced in patients with systemic sclerosis.

Authors:  Vivien M Hsu; Eszter Kozák; Qiaoli Li; Márta Bocskai; Naomi Schlesinger; Ann Rosenthal; Scott T McClure; László Kovács; László Bálint; Szilvia Szamosi; Gabriella Szücs; Mary Carns; Kathleen Aren; Isaac Goldberg; András Váradi; John Varga
Journal:  Rheumatology (Oxford)       Date:  2022-03-02       Impact factor: 7.046

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.